NCT06666270View on ClinicalTrials.gov

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
Advanced Solid CancerMetastatic Solid TumorOvarian CancerBreast CancerProstate CancerBRCA MutationHRR Deficiency
Interventions
DRUG

SYN818

Patients will orally receive SYN818

Trial Locations (2)

200032

RECRUITING

Fudan University Shanghai Cancer Center., Shanghai

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

INDUSTRY